Head to head
Henry Schein vs McKesson
Side-by-side on the measures that matter, with a plain-English read. Full detail: HSIC · MCK
HSIC
Henry Schein
83.66-1.39%
1-year price shape — +29% over the period
Quant Rating C · 68/100
vs
MCK
McKesson
910.33-1.23%
1-year price shape — +22% over the period
Quant Rating C · 65/100
1-year performance, rebased to 100
McKesson edges it on the scoreable measures. McKesson trades cheapest on trailing earnings; McKesson pays the highest dividend yield; McKesson earns the most per share.
| HSIC | MCK | |
|---|---|---|
| Snapshot | ||
| Sector | Medical Distribution | Medical Distribution |
| Last price | 83.66 | 910.33 |
| Change today | -1.39% | -1.23% |
| 1-year return | +28.9% | +21.8% |
| Market cap | $9.32B | $106.14B |
| 52-week range | 61.95 – 92.18 | 722.11 – 996.84 |
| Valuation | ||
| P/E (TTM) | 24.39 | 24.31 |
| P/E percentile, own 5-yr range | 83rd | 45th |
| P/B | 2.95 | -25.03 |
| Dividend yield | 0.00% | 0.36% |
| Profitability & growth | ||
| EPS (TTM) | 3.27 | 38.55 |
| Net profit (TTM) | $364.43M | $4.49B |
| Revenue (TTM) | $13.60B | $410.98B |
| Revenue growth (YoY) | +6.7% | +7.7% |
| Gross margin | 31.3% | 3.6% |
| Operating margin | 5.7% | 1.7% |
| Net margin | 3.0% | 1.1% |
| Free cash flow (TTM) | $513.00M | $6.15B |
| Ownership & sentiment | ||
| Institutional ownership | 114.9% | 92.0% |
| Insider activity (12mo) | 25 buy / 22 sell | 23 buy / 25 sell |
| Short interest (% of float) | 6.8% | 2.5% |
| Analyst consensus | 69% buy / 31% hold (13) | 83% buy / 17% hold (12) |
| Analyst price target | $103 (+23%) | $1,001 (+10%) |
| StockVane view | ||
| StockVane Quant Rating | C (68) | C (65) |
| Company | ||
| Employees | 25,000 | 43,000 |
| Founded | 1932 | 1833 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.